IONS – ionis pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
12/17
07:06 am
ions
Low
Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/15
11:07 am
ions
Low
Ionis Pharmaceuticals (NASDAQ:IONS) was given a new $100.00 price target on by analysts at Leerink Partners.
12/15
04:31 am
ions
Low
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe [Yahoo! Finance]
12/9
01:15 pm
ions
Low
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Bank of America Corporation from $86.00 to $97.00. They now have a "buy" rating on the stock.
12/3
11:14 am
ions
Low
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
10/29/2025
07:00 am
IONS
-2.9%
BEAT
7/30/2025
07:00 am
IONS
4.5%
BEAT
4/30/2025
07:00 am
IONS
1.4%
BEAT
2/19/2025
07:00 am
IONS
-1.6%
BEAT
12/17
10:01 am
Maintains
Outperform
Outperform
RBC Capital
Low
-2.0%
12/17
10:01 am
Maintains
Outperform
Outperform
RBC Capital
Low
-2.0%
12/17
07:06 am
Reiterates
Outperform
Outperform
Royal Bank Of Canada
Low
-1.7%
12/17
07:06 am
Reiterates
Outperform
Outperform
Royal Bank Of Canada
Low
-1.7%
12/15
03:44 pm
Maintains
Outperform
Outperform
Leerink Partners
Low
0.2%
12/3
07:01 pm
ions
Low
Form 4 IONIS PHARMACEUTICALS For: Dec 01 Filed by: WENDER JOSEPH H
12/1
06:46 pm
ions
Low
Form 144/A IONIS PHARMACEUTICALS Filed by: WENDER JOSEPH H
12/1
06:14 pm
ions
Low
Form 144 IONIS PHARMACEUTICALS Filed by: WENDER JOSEPH H
11/28
05:52 pm
ions
Low
Form 4 IONIS PHARMACEUTICALS For: Nov 25 Filed by: Devers Shannon L.
11/28
05:52 pm
ions
Low
Form 4 IONIS PHARMACEUTICALS For: Nov 25 Filed by: KLEIN JOSEPH III
Show more
Top News Gainers
3/23 Form 4 IONIS PHARMACEUTICALS For: Mar 19 Filed by: CROOKE STANLEY T 7.8%
3/3 Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: O'NEIL PATRICK R. 7.6%
3/26 Ionis Pharmaceuticals Inc (NASDAQ: IONS) had its price target lowered by analysts at Cantor Fitzgerald from $65.00 to $56.00. They now have a "neutral" rating on the stock. 6.4%
4/8 Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs 4.9%
7/17 Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: McDevitt Damien 4.5%
9/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. 4.4%
4/23 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
2/16 Ionis Pharmaceuticals Looks Undervalued - Q4, FY Earnings Will Be Important [Seeking Alpha] 3.6%
9/10 Ionis Pharmaceuticals, Inc. (IONS) Presents at 17th Annual Morgan Stanley Global Healthcare Conference (Transcript) [Seeking Alpha] 3.2%
8/7 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.270 ActVsEst 0.260 - Beat 3.2%
Top News Decliners
3/15 Researchers Behind Spinraza Win Breakthrough Prize [Forbes] -9.9%
7/22 Biogen Earnings: Here's What Investors Are Hoping To See In Report [Investor's Business Daily] -8.8%
3/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.0%
10/16 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.6%
3/20 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $49.00 price target on the stock. -5.4%
2/26 Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.9%
6/6 Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders -4.7%
9/30 Form 8-K IONIS PHARMACEUTICALS For: Sep 27 -4.6%
2/28 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.2%
12/16 Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial -3.8%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3